Reliability of symmetric dimethylarginine in dogs with myxomatous mitral valve disease as kidney biomarker by A. Savarese et al.
Open Veterinary Journal, (2018), Vol. 8(3): 318-324 
ISSN: 2226-4485 (Print) Original Article 
ISSN: 2218-6050 (Online) DOI: http://dx.doi.org/10.4314/ovj.v8i3.11 
 
________________________________________________________________________________________________________
*Corresponding Author: Alice Savarese. Department of Veterinary Medicine (DIMEVET), University of Milan, via Celoria 10, 
20133 Milan, Italy. Tel.: +39 0250318167. Email: alice.savarese@unimi.it 318 
_____________________________________________________________________________________________ 
Submitted: 23/02/2018 Accepted: 03/08/2018 Published: 19/08/2018 
 
Reliability of symmetric dimethylarginine in dogs with myxomatous mitral 
valve disease as kidney biomarker 
 
Alice Savarese‡,*, Monica Probo‡, Chiara Locatelli, Sergio Aurelio Zanzani, Alessia Libera Gazzonis, Melissa Papa 
and Paola Giuseppina Brambilla 
 
Department of Veterinary Medicine (DIMEVET), University of Milan, via Celoria 10, 20133 Milan, Italy 
‡Both authors contributed equally to this work 
_____________________________________________________________________________________________ 
Abstract 
The most common cause of heart failure in the canine population is myxomatous mitral valve disease, sometimes 
complicated by chronic kidney disease. Many studies have been done on the use of symmetric dimethylarginine as 
biomarker of renal impairment in dogs affected by chronic kidney disease, few studies have examined his reliability 
as biomarker in dogs affected by heart diseases. Aim of this study was to evaluate symmetric dimethylarginine in dogs 
affected by mitral valve disease in order to assess his reliability in heart diseases. This was a retrospective case-control 
study on a clinical population of dogs affected by mitral valve disease (cases) vs healthy dogs (controls). Both groups 
underwent a complete physical evaluation, echocardiographic examination, complete blood count, biochemical panel, 
including serum creatinine and urea and urine analysis with protein-to-creatinine ratio. Serum was frozen and sent to 
IDEXX laboratories for symmetric dimethylarginine determination. General linear model was applied to data. A total 
number of 24 cases and 7 controls were included. Symmetric dimethylarginine value was in the reference value in the 
75% (n=18) of cases, and in the 43% (n=3) of controls. Once set symmetric dimethylarginine as dependent variable, 
no statistical significant differences were found for each variable considered (breed, age, sex, weight, class of 
cardiomyopathy, presence/absence of valvular disease, presence/absence of congestive heart failure, pharmacological 
therapy, creatinine and urea concentration). Blood concentration of SDMA resulted not influenced by the variables 
mentioned above, so it could be considered a reliable marker of early renal impairment in dogs affected by mitral 
valve disease. 
Keywords: Biomarker, Cardiovascular-renal disorder, Dog, Myxomatous mitral valve disease, Symmetric 
dimethylarginine. 
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Introduction 
The most common acquired heart disease affecting 
dogs and leading to congestive heart failure (CHF) is 
myxomatous mitral valve disease (MMVD), also 
known as endocardiosis, that can reach a prevalence of 
100% in small breed dogs in their old age (Mattin et al., 
2015).  
The presence of both heart and kidney failure can be 
defined as cardiorenal syndrome (CRS) (Ronco, 2010; 
Ronco and Maisel, 2010). In 2015, a Consensus Group 
was formed to develop definitions and 
recommendations for CRS approach in veterinary 
medicine (Pouchelon et al., 2015). The consensus 
renamed CRS as “Cardiovascular-Renal Disorder” 
(CRvD) and defined it as a “disease, toxin or drug-
induced structural and/or functional damage to the 
kidney and/or cardiovascular system, leading to 
disruption of the normal interactions between these 
systems, to the ongoing detriment of one or both” 
(Pouchelon et al., 2015).  
Martinelli et al. (2016), reported a 25% prevalence of 
chronic kidney disease (CKD) associated with 
hyperazotemia in dogs with MMVD. Moreover, the 
presence of CKD associated to MMVD in dogs 
decreases survival time (Martinelli et al., 2016).  
An early diagnosis of renal impairment in patients 
affected by cardiovascular disease is therefore very 
important. Glomerular filtration rate (GFR) is currently 
considered the gold standard for quantitative 
determination of kidney filtration, although not 
routinely performed on dogs and cats. In fact, the 
procedure requires the intra-venous injection of a 
marker of filtration, followed by multiple blood 
samples at determined time, making the process 
expensive and time consuming (Relford et al., 2016; 
Yerramilli et al., 2016).  
Currently, the cornerstone in the diagnosis of CKD in 
veterinary practice is the measurement of serum 
Creatinine (sCr), that is the most common marker of 
GFR. Indeed, the use of sCr has some limitations, since 
its concentration tend to rise when almost the 75% of 
the renal activity is lost and its levels are affected by 
muscle mass, making the evaluation of renal function 
more difficult in cachectic and geriatric animals.  
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Many studies have been carried out to assess the 
efficacy of novel biomarker in the early detection of 
kidney failure. Due to its characteristics, symmetric 
dimethylarginine (SDMA) has raised, in the last few 
years, as the most promising novel biomarker in the 
early detection of kidney failure. SDMA is one of the 
methylated forms derived from the arginine 
metabolism, with asymmetric dimethylarginine 
(ADMA) and monomethylarginine (MMA) (Kakimoto 
and Akazawa, 1970). While ADMA is largely cleared 
by enzymatic hydrolysis, SDMA is primarily 
eliminated by renal excretion (McDermott, 1976), 
suggesting its role as endogenous marker of GFR 
(Kielstein et al., 2006; Schwedhelm and Böger, 2011). 
SDMA increases earlier than creatinine and can 
identify a GFR decline as early as a 30% (Polzin, 2016). 
A large meta-analysis from Kielstein et al. (2006) 
showed that SDMA strongly correlated with inulin 
clearance and sCr. A study from Relford et al. (2016) 
reported that age and lean body mass cannot influence 
SDMA concentration in small animals. 
Major non-renal systemic disease, including hepatic 
and endocrine diseases have not been consistently 
identified as reasons of elevation in serum SDMA 
concentrations, neither in humans nor in animals, and 
the effects of both heart and kidney failure on SDMA 
elimination are still undefined (Schwedhelm and 
Böger, 2011; Veldink et al., 2013; Bum-Sul et al., 
2017). 
The aim of this study was to determine the reliability of 
serum SDMA as a marker of early renal impairment in 
dogs affected by MMVD in different American College 
of Veterinary Internal Medicine (ACVIM) classes, and 
with sCr within the normal range of values. 
Materials and Methods 
This was a retrospective case-control study on a clinical 
population of dogs affected by MMVD (cases) vs 
healthy dogs (controls). The animals enrolled belonged 
to the population of dogs referred to the Cardiology 
Service of our institution between February 2015 and 
July 2016.  
Inclusion criteria were: diagnosis of MMVD, absence 
of any other concurrent pathology and no 
hematological alteration compatible with CKD (sCr < 
1,4 mg/dl). Dogs with other heart or systemic diseases 
were excluded. Control group was composed by 
healthy dogs that were evaluated at the veterinary 
teaching hospital for periodic screening and then 
enrolled. For all dogs, informed consent for every 
procedure signed by the owner was obtained, as 
routinely done in our clinical practice.  
Both groups underwent a complete physical evaluation, 
chest x-ray, echocardiographic examination, complete 
blood count (CBC) and serum biochemical panel. A 
complete echocardiographic examination was 
performed in both groups using standardized thoracic 
imaging planes, according to the recommendations of 
the American Society of Echocardiography (Thomas et 
al., 1993). Dogs without any clinical, radiographic and 
echocardiographic sign of cardiac disease were 
enrolled as controls. Echocardiography was performed 
using an Esaote MyLab50 Gold cardiovascular, with 
phased array multifrequency probes (7.5-10 Mhz and 
2.5-3 Mhz).  
The investigators performing the echocardiographic 
exams were all focused on specialty cardiology practice 
(AS, CL, PGB). Dogs diagnosed with MMVD were 
subdivided in 4 classes, from B1 to D, in line with the 
ACVIM classification. As recommended by the 
ACVIM guidelines, stage B included dogs affected by 
MMVD without signs of CHF (namely, in stage B1, 
dogs without evidence of cardiac enlargement; in B2, 
dogs with signs of cardiac remodeling as left atrium 
(LA) and/or left ventricle (LV) enlargement); stage C 
included dogs with clinical signs of CHF due to 
MMVD, and stage D included subjects presenting both 
clinical signs of CHF and refractoriness to standard 
medical treatments (Atkins et al., 2009; Boswood et al., 
2016).  
All dogs underwent indirect systemic blood pressure 
evaluation by Doppler flow meter as reported in 
ACVIM guidelines (Brown et al., 2007). Based on the 
International Renal Interest Society (IRIS) guidelines, 
dogs were classified in 5 classes, from 0 to 4. No 
azotemic patients (normal sCr) were enrolled, and all 
the dogs were classified as IRIS class 0 (dogs at risk for 
the development of CKD). An IRIS substage of CKD 
based on blood pressure and on the presence of 
proteinuria was performed, when possible, as reported 
in the IRIS guidelines (IRIS, 2016). 
Blood samples were collected from the cephalic vein 
during routine clinical evaluation, and CBC and 
selected biochemical parameters were performed. For 
CBC, EDTA was used as anticoagulant, while, for 
biochemical evaluation, blood was placed in tubes 
without anticoagulant and centrifuged at 3250 x g for 5 
minutes. CBC was performed using an automated laser 
hematology analyzer (Sysmex XT-2000iV, Sysmex 
corporation, Kobe, Japan), while biochemistry was 
carried out with an automated spectrophotometer 
(Roche Cobas Mira Classic Biochemistry Analyzer).  
The biochemical panel performed was composed by: 
glucose, urea, sCr, total proteins, sodium, potassium, 
chloride, alanine transaminase, alkaline phosphatase. 
An aliquot of serum (at least 300 μl) was frozen and 
sent to IDEXX laboratories for SDMA determination 
with the EMIT (Enzyme Multiplied Immunoassay 
Technology). SDMA in dog was considered normal 
when < 14 μg/dL (Nabity et al., 2015). Urine were 
collected via spontaneous micturition or cystocentesis 
and complete urinalysis with sediment and Urine 
Protein to Creatinine Ratio (UPC) was performed.  
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Normality of data distribution was tested with Shapiro 
- Wilk test. For baseline descriptive statistics, normally 
distributed continuous variables were presented as 
mean and standard deviation, non- normally distributed 
variables as median and interquartile range (IQR). Data 
were analyzed with IBM SPSS Statistics 23 [Release 
23.0.0.0] using a multivariate generalized linear model 
(GLM) with backward elimination, applied on ACVIM 
class (compared with breed, sex, age, weight, SDMA 
values, Urea values and sCr values) and on SDMA 
(compared with breed, sex, age, weight, MVD presence 
or absence, ACVIM class, presence of clinical 
symptomatology, pharmacological therapy, Urea 
values and sCr values).  
To apply the model, a transformation of ACVIM 
classes into numbers categories was made, with 
ACVIM class B1 corresponding to 1, ACVIM B2 to 2, 
ACVIM C to 3 and ACVIM D to 4. We evaluated if 
severity of MMVD, CHF symptomatology or 
pharmacological treatment can influence a single 
measurement of SDMA levels in dogs affected by the 
MMVD. P < 0.05 was set to indicate statistical 
significance.  
Results 
An overall number of 367 privately owned dogs were 
admitted to the Cardiology Service of DIMEVET of the 
University of Milan between February 2015 and July 
2016; among these, 148 (40%) were diagnosed with 
MMVD. The medical archives were reviewed in order 
to include only patients with complete medical and 
laboratory information. Thirty-one dogs were enrolled, 
24 in the case group and 7 in the control group.  
The median age of dogs enrolled in case group was 11.5 
years (±2.83 SD), and the median body weight was 13.8 
kg (±9.91 SD). Most of the dogs included were 
neutered females (n=11; 46%), followed by intact 
males (n=8; 33%), intact females (n=3; 12%) and 
neutered males (n=2; 9%). The most represented breeds 
were Mongrels (n=8; 33%), Cavalier King Charles 
(n=2; 8%), Chihuahua (n=2; 8%) and Maltese dogs 
(n=2; 8%). Breeds with less than two dogs were 
grouped and listed as others (51%). In this group were 
also listed Dachshund and Jack Russel terrier.  
The median age of the control group was 8.2 years 
(±1.92 SD), and the median body weight was 21 kg 
(±9.17 SD). Most of the controls included were 
neutered females (n=5; 71%), followed by intact males 
(n=2; 29%). The most represented breed were mongrels 
(n=3; 43%). Thirteen dogs over 24 were classified as 
ACVIM B1 (54%), 8 as ACVIM B2 (33%) and 3 as 
ACVIM C (13%). Symptomatic and non-symptomatic 
dogs for CHF were respectively 13% (n=3) and 87% 
(n=21). The 3 dogs classified as ACVIM class C were 
all under standard triple therapy, composed by 
furosemide, an ACE inhibitor, and pimobendan.  
Renal function was tested measuring serum urea, sCr 
and SDMA. sCr was normal in all dogs, as it was an 
inclusion criteria. Serum urea (NV= 20 – 60 mg/dL) 
was over the reference interval in 8 of the cases (33%). 
None of the controls presented alterations in urea 
values.  
The 25% (n=2) of dogs classified as ACVIM B1 
presented urea values above the reference interval, so 
the 24% (n=3) of ACVIM B2 and the 100% of ACVIM 
C. Only medical records of dogs presenting urinalysis 
were retrospectively included. Urine specific gravity 
(USG) was normal (NV=1020 - 1060) in 87% of cases 
(21/24) and in 100% of the controls for which urinalysis 
was available. For the case group, 2/3 dogs presented 
USG lower than reference interval (66%), while one 
presented USG over the reference interval (34%). Both 
of the dogs with low USG were classified as ACVIM C 
and were assuming furosemide. No proteinuria was 
detected in any of the dog considered (UPC < 0.5) (IRIS 
2016). SDMA value was normal (< 14 μg/dL) in the 
75% (n=18) of cases, and over the reference interval in 
the 25% (n=6). The 31% of the ACVIM B1 dogs (4/13) 
and the 25% of the ACVIM B2 (2/8) presented SDMA 
values over the reference interval. None of the dogs 
classified as ACVIM C had SDMA above the 
references. SDMA was above the reference intervals in 
4/7 of controls (57%).  
According to the new IRIS guidelines, the 25% of 
MMVD dogs should be shifted from IRIS class 0 to 
IRIS class 1, while the 57% of dogs classified as 
controls switched form IRIS class 0 to IRIS class 1.  
Once set SDMA as dependent variable in the GLM, the 
results showed no statistical significant difference for 
each variable considered (breed, age, sex, weight, 
ACVIM class, healthy/affected, presence of CHF 
symptomatology, pharmacological therapy, sCr, urea) 
(Table 1, Table 2). 
Once set ACVIM class as dependent variable in the 
GLM, the results only showed a statistical significant 
difference in the variable age for higher ACVIM 
classes (C) (P = 0.014; OR = 1.3) (Table 3, Table 4). 
Discussion 
The population of dogs affected by MMVD enrolled in 
this study presented the typical characteristics reported 
in literature. In fact, the dogs were mainly of medium 
age and body weight, mongrels or pure small breed 
dogs (Borgarelli and Buchanan, 2012). Most of the 
dogs were asymptomatic for CHF (87%). Age resulted 
correlated with ACVIM classes, as reported in 
literature (Borgarelli and Buchanan, 2012). 
Interestingly, multivariate analysis showed that for 
each year of life of the dog, the risk of belonging to a 
higher ACVIM class increases of 1.3 times.  
According to literature, the prevalence of azotemia in 
dogs with heart diseases ranges between 7.4 and 25%. 
(Atkins et al., 2002; Nicolle et al., 2007; Guglielmini et 
al., 2013; Martinelli et al., 2016).  
http://www.openveterinaryjournal.com 
A. Savarese et al.  Open Veterinary Journal, (2018), Vol. 8(3): 318-324 
________________________________________________________________________________________________________ 
 
321 
Table 1. Linear generalized univariate model analysis with binomial negative response; dependent variable: SDMA. 
 
Variable Factor OR 
IC 95% 
p-value 
INF SUP 
Sex 
F 1.661 0.153 18.075 0.677 
FC 1.072 0.166 6.931 0.942 
M 1.397 0.212 9.200 0.728 
MC (reference) 1    
Breed 
Mongrel 1.036 0.357 3.012 0.948 
Pure (reference) 1    
Age (years) Continuous Variable 1.032 0.855 1.246 0.740 
Weight (Kg) Continuous Variable 0.994 0.937 1.055 0.848 
sCr (mg/dL) Continuous Variable 4.865 0.070 339.044 0.465 
Serum urea (mg/dL) Continuous Variable 0.997 0.963 1.033 0.862 
ACVIM Continuous Variable 0.804 0.321 2.013 0.641 
CHF symptoms 
No 1.241 0.052 29.905 0.894 
Yes (reference) 1    
Pharmacological treatment (CHF) 
ACE-inhibitor 1.361 0.231 8.013 0.733 
ACE- inhibitor and diuretic 1.317 0.052 33.426 0.868 
ACE- inhibitor and inotropic agent 2.219 0.025 198.372 0.728 
ACE- inhibitor, inotropic agent and diuretic 1.681 0.101 27.989 0.717 
No treatment (reference) 1    
 
Table 2. Linear generalized multivariate model analysis with binomial negative response [after backward elimination]; dependent 
variable: SDMA 
 
Variable Factor OR 
IC 95% 
p-value 
INF SUP 
sCr (mg/dL) Continuous Variable 2.143 0.242 19.001 0.494 
 
Table 3. Linear generalized univariate model analysis with ordinal logistic response; dependent variable: ACVIM. 
 
Variable Factor OR 
IC 95% 
p-value 
INF SUP 
Sex 
F 10.015 0.175 573.395 0.265 
FC 0.458 0.024 8.880 0.606 
M 15.623 0.754 323.923 0.076 
MC (reference) 1    
Breed 
Mongrel 1.270 0.214 7.542 0.793 
Pure (reference) 1    
Age (years) Continuous Variable 1.300 0.924 1.829 0.132 
Weight (Kg) Continuous Variable 0.929 0.843 1.023 0.135 
sCr (mg/dL) Continuous Variable 15.479 0.502 477.462 0.117 
Serum urea (mg/dL) Continuous Variable 1.036 0.975 1.101 0.253 
 
Table 4. Linear generalized multivariate model analysis with ordinal logistic response; dependent variable: ACVIM 
 
Variable Factor OR 
IC 95% 
p-value 
INF SUP 
Age (years) Continuous Variable 1.323 1.058 1.656 0.014 
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In our population, all dogs presented normal sCr values. 
No statistically significant differences in urea values 
have been found among different ACVIM classes, 
although a positive increasing trend is evident and the 
totality of dog in ACVIM class C presented urea values 
above the reference interval. The progression of 
MMVD and the development of CHF reduce renal 
perfusion and can result in urea increase (Aronson et 
al., 2004; Kazory, 2010). Also, the activation of the 
renin angiotensin aldosterone system (RAAS), which 
increases the absorption of sodium and water, can 
contribute (Aronson et al., 2004; Kazory 2010). The 
increase may also be due to the administration of 
diuretic drugs, prescribed for ACVIM class C patients 
(Atkins et al., 2009; Pouchelon et al., 2015). 
The 75% of patients at any stage of MMVD presented 
normal values of SDMA. SDMA has been compared 
with all the variables considered in our study, and none 
of them gave statistically significant result. SDMA 
appears as a promising early biomarker of kidney 
function in patients affected by any stage of MMVD, 
since the presence of this cardiovascular disease 
doesn’t result in influences on the parameter. 
According to literature, our study showed that SDMA 
is not influenced by lean body mass and weight (Hall et 
al., 2015), differently from creatinine; therefore, those 
data cannot be considered as confounding factors. 
Moreover, SDMA is not influenced by age: this is an 
important aspect since the canine population affected 
by MMVD is usually in the old age. Pedersen et al. 
(2006) reported also that SDMA levels were not altered 
by the presence of asymptomatic mitral regurgitation, 
but the study did not consider any dog presenting CHF 
and was conducted only on Cavalier King Charles 
Spaniels dogs (Pedersen et al., 2006). 
More recently, Bum-Sul et al. (2017) reported that 
SDMA levels in dogs with MMVD, mostly 
symptomatic, were not correlated to age or body 
weight, but closely correlated to the severity of HF and 
some echocardiographic markers, like LA/Ao ratio 
(Bum-Sul et al., 2017). Based on our population, since 
SDMA is considered a biomarker of GFR (Nabity et al., 
2015), our data seems to suggest that the 25% of our 
population could present a reduction of GFR despite the 
normal sCr values. Even the comparison between 
SDMA and creatinine didn’t result statistically 
significant, differently from what reported in literature 
(Nabity et al., 2015), but this data is probably 
attributable to the inclusion criteria used in this study. 
In fact, all the patients presented normal creatinine 
values.  
It can be noted that, in the control group, there was a 
greater percentage of patients with SDMA values 
higher than normal compared to the group of cases 
(25% vs 57%): this result is of difficult interpretation 
since, in veterinary medicine, few studies have been 
made about influences other than CKD on SDMA 
values and due to the lack of information about 
abdominal ultrasound. However, all control dogs in our 
population presented normal urinary specific gravity 
and no proteinuria, so kidney damage seems less likely. 
Many different causes have been investigated to justify 
high levels of SDMA and ADMA concentration in 
human patients, like in diabetes (Krzyzanowska et al., 
2007) or sepsis (Koch et al., 2013), but all the principal 
diseases that can alter SDMA values have been 
excluded from our population. We cannot exclude the 
presence of pre-analytical errors in SDMA 
determination. Moreover, a recent study reported the 
presence of a small percentage of animals with elevated 
SDMA but normal sCR in which kidney function must 
be assessed (Polzin, 2016).  
Although no agreement is present on the therapeutic 
options in dog presenting alteration of SDMA without 
other signs of renal impairment, the evaluation of this 
parameter could be important from a clinical point of 
view, and allows us to suggest for these patients a more 
targeted diagnostic procedure with a full assessment of 
kidney function, including second evaluation of SDMA 
within one month, complete biochemical renal profile 
examination (creatinine and urea), urinalysis with UPC 
ratio and ultrasound renal evaluation, as recommended 
by IRIS guidelines (IRIS, 2016). Moreover, according 
to Hall et al. (2017) the administration of a renal diet to 
dogs currently classified as IRIS-Stage 1 CKD can 
result in reduction of blood concentration of kidney 
biomarkers, in particular SDMA and sCr, besides 
improving patient’s quality of life (Hall et al., 2017). A 
previous longitudinal study on geriatric dogs fed with 
commercial renal protective food showed that dogs 
consuming test food showed significant reduction in the 
concentrations of serum SDMA, sCr, and BUN. 
Moreover, serum sodium concentrations were seen to 
be statistically significant lower in dogs assuming this 
kind of diets, that can be of help in dogs with heart 
disease in which restriction of sodium is indicated. 
Finally, a kidney protection food containing more 
biologically available protein sources with respect to 
other commercially available dry foods could be of help 
in preventing cardiac cachexia, loss of muscular masses 
and mobility in patients affected by MMVD at various 
gravity levels (Hall et al., 2016). This is a retrospective 
study and, as such, has some inherent limitations. 
Firstly, the abdominal ultrasound was not 
systematically assessed in our population of dogs. 
Secondly, the small number of animals included in 
higher ACVIM class C and the single determination of 
the parameter could affect the statistical significance 
and must be taken into account in future studies. In fact, 
a single determination of SDMA, not followed by a 
second reevaluation within one month or abdominal 
imaging, cannot be considered diagnostic of CRvD.  
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In conclusion, our study showed that SDMA is free 
from correlation with breed, age, sex, weight, 
presence/absence of MMVD, presence of CHF 
symptoms and pharmacological therapy as well. 
SDMA can be actually considered a reliable parameter 
for evaluation of renal function in dogs affected by 
MMVD, especially in those patients with a non-
advanced stage of disease (ACVIM class B2), for 
which an early diagnosis of the onset of kidney failure 
is fundamental in order to plan a diuretic therapy. 
SDMA repeated measurements over time, as 
recommended by IRIS guidelines, are necessary (IRIS, 
2016), because one determination does not allow us to 
exclude definitely a later onset of the renal impairment 
and then to be considered diagnostic in order to 
highlight a possible onset of CRS. 
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